The medication is considered relevant for Type 2 Diabetes Mellitus in adults. It is commonly used as a relevant component of a treatment plan alongside diet and exercise, and may assist with managing glycemic control.

---

Understanding the Therapeutic Scope

This combination is commonly applied in clinical settings where patients experience difficulty managing blood sugar levels, which remain elevated despite initial efforts with Metformin alone. The medication is relevant for easing symptoms related to systemic imbalance, such as elevated blood sugar and fluctuating glucose levels. It is used to address insufficient glycemic control and as part of combination therapy with other agents, such as Insulin or Sulfonylureas.

“The overall benefit is that the medication supports a sense of stability when symptoms are more noticeable, and may assist with managing blood sugar fluctuations.”

The medication assists with managing symptoms that create noticeable physiological strain, is relevant for easing the overall symptom load, and may help patients cope more steadily with symptom fluctuations. The extended-release, fixed-dose format supports general well-being during symptomatic phases and may assist with maintaining functional stability by simplifying the treatment regimen.

---

Quick Fact: Relief for Fluctuating Glucose Levels This medication is commonly used to help patients cope more steadily with symptom fluctuations and manage chronic high blood sugar.

Янумет Лонг is indicated for use exclusively in adults with Type 2 Diabetes Mellitus. Eligibility is strictly governed by official regulatory standards, which establish several population exclusions and restrictions.

Populations for whom use is contraindicated

• Severe Renal Impairment: Estimated Glomerular Filtration Rate (eGFR below 30 mL/min/1.73 m²).
• Metabolic Acidosis: Including diabetic ketoacidosis.
• Type 1 Diabetes Mellitus.
• History of a serious hypersensitivity reaction to either sitagliptin or metformin components.

Condition-specific eligibility rules

Use is generally avoided in patients with hepatic impairment. Initiation of therapy is not recommended in patients with moderate renal impairment (eGFR between 30 and <45 mL/min/1.73 m²).

Age-related eligibility rules

The medicine's safety and effectiveness have not been established for the pediatric population (under 18 years). Older adults (65 years and older) require more frequent assessment of renal function.

Pregnancy and lactation eligibility status

Use is not recommended during pregnancy or while breastfeeding.

Eligibility-related restrictions

The medicine requires temporary discontinuation prior to certain radiological procedures involving iodinated contrast materials or during major surgery.

The official regulatory profile for Янумет Лонг (Metformin and Sitagliptin) documents several interaction patterns, primarily centered on the Metformin component's elimination and the combined pharmacodynamic effects.

Documented Interactions and Restrictions

Interaction Entity	Regulatory Description & Restriction
Iodinated Contrast Agents	Contraindicated Combination tied to procedure timing. Metformin must be temporarily interrupted at the time of or prior to the imaging procedure and withheld afterward, until renal function is assessed and stable.
Renal Transporter Inhibitors	Co-administration with inhibitors of OCT2 and MATE1 transporters (e.g., Cimetidine, Verapamil, Ranolazine) increases Metformin plasma concentrations ( C max and AUC) by decreasing its renal clearance.
Other Antidiabetic Agents	A pharmacodynamic additive effect increases the formal risk of hypoglycemia when combined with agents like Insulin or Sulfonylureas.
Alcohol	Excessive consumption increases the documented risk of Metformin-associated lactic acidosis, particularly in the presence of factors like fasting or hepatic impairment.
Hyperglycemia-Inducing Agents	Agents such as Glucocorticoids and some Diuretics can counteract the drug's intended action, requiring closer monitoring of glycemic control.

Population-Specific Note: The severity of Metformin-related interactions, particularly the risk of lactic acidosis, is documented as being heightened in patients with renal impairment due to reduced drug clearance.

How Янумет Лонг Works: Mechanism of Action

Янумет Лонг combines the distinct mechanisms of Metformin and Sitagliptin to co-modulate circulating glucose concentrations.

Metformin acts primarily on the liver by inhibiting the Mitochondrial Respiratory-Chain Complex I. This alteration in cellular energy status activates the AMPK pathway, which lowers the expression of genes encoding gluconeogenic enzymes. This action reduces the amount of new glucose released into the systemic circulation, which modulates the baseline plasma glucose concentration.

Sitagliptin functions as a highly selective inhibitor of the DPP-4 enzyme. By blocking DPP-4 degradation, Sitagliptin raises the circulating concentration of active incretin hormones ( GLP-1 and GIP). The increased incretin signaling augments insulin secretion and reduces glucagon release from the pancreas, specifically when the plasma glucose concentration is elevated (glucose-dependent action).

This complementary, dual-mechanism approach impacts both hepatic glucose output and pancreatic hormonal response, leading to a comprehensive co-modulation of systemic glucose levels.

Янумет Лонг is a fixed-dose combination Antihyperglycaemic Agent administered orally. The medication is designed for a consistent routine, requiring that the extended-release tablet be taken once daily. The medication is administered with a meal, and is typically recommended to be taken with the evening meal to support consistent therapeutic levels. The available fixed strengths range up to a maximum daily dose of 100 mg Sitagliptin and 2000 mg Metformin extended-release.

A core procedural instruction is that the tablets must be swallowed whole and must not be split, crushed, or chewed. This requirement is essential for the extended-release properties of the Metformin component to function correctly over the 24-hour dosing period.

Dosing is individualized based on the patient’s prior regimen, and dose escalation is gradual to improve tolerability. A crucial constraint on usage is based on renal status: renal function (eGFR) is assessed before and during treatment. The dose of the Sitagliptin component is limited to 50 mg once daily if the patient’s eGFR falls below 45 mL/min/1.73 m^2. Usage is not established for pediatric patients under 18 years of age. If a dose is missed, it should be taken when remembered, but two doses must never be taken together.

Research evidence / Overview of studies for Янумет Лонг

---

Evidence for Use as Initial Therapy for Type 2 Diabetes

The combination of sitagliptin and extended-release metformin was evaluated in research as an initial therapy for adults with inadequate glycemic control through diet and exercise alone. These studies explored how the medicine performed compared to placebos or other active diabetes medications. Researchers observed key markers, notably Glycated Hemoglobin (HbA1 c) and Fasting Plasma Glucose (FPG), which are standard biomarkers related to blood sugar regulation. The trials reported measurements of HbA1 c and FPG that were collected in the groups taking the combination medicine over intermediate-term observation periods.

---

Evidence for Use as Add-on Therapy

The combination medicine was evaluated in scenarios where it was administered alongside existing medication. These randomized trials explored short-term symptom changes in adults with Type 2 Diabetes who had inadequate glycemic control while on a stable regimen of another drug, including Metformin alone or dual therapy with Insulin or a Sulfonylurea. Findings describe patterns observed in the studies across these different add-on regimens.

Trial Design for the Extended-Release Formulation

The specific extended-release (XR) nature of Янумет Лонг was also the subject of dedicated research. These Bioequivalence (BE) studies examined whether the once-daily XR tablet's absorption profile was comparable to taking the standard immediate-release components separately.

---

Research Gaps and Unstudied Areas

While evidence contributes to understanding short-term symptom patterns, long-term effects are not fully established. Data for certain groups remain insufficient. Specifically, the effectiveness and safety was not established in pediatric patients (children and adolescents). Furthermore, the combination was not evaluated in patients with a prior history of pancreatitis, meaning research does not determine whether an individual with this specific history will respond similarly to the studied population.

Common questions about Янумет Лонг (FAQ)

---

Q: Can older adults use Янумет Лонг?

According to official documentation, the medication should be used with caution in older adults (65 years and older). Because the drug's components are excreted by the kidneys, this population requires more frequent assessment and monitoring of their kidney function (eGFR). Monitoring is required to help assess the risk of a serious complication called lactic acidosis, which is linked to impaired kidney function.

---

Q: Is Янумет Лонг safe for people with liver problems?

Regulatory guidance states that the use of this medication is generally avoided in patients with hepatic impairment (liver problems). The presence of liver impairment increases the documented risk of metformin-associated lactic acidosis, a serious and life-threatening metabolic complication.

---

Q: Can Янумет Лонг cause pancreatitis?

Cases of acute pancreatitis (inflammation of the pancreas) have been reported in patients using sitagliptin, one of the components of this medicine. Official documentation indicates that the medicine is generally discontinued immediately if pancreatitis is suspected.

---

Q: Can taking Янумет Лонг cause a rash or allergic reaction?

Yes, serious hypersensitivity reactions (allergic reactions) have been reported in post-marketing surveillance. These reports have included severe allergic reactions like swelling (angioedema), anaphylaxis, severe skin conditions like Stevens-Johnson syndrome, and rash. Regulatory documents state that discontinuation of the medicine is recommended if a serious allergic reaction occurs.

---

Q: Is Янумет Лонг suitable for use in children?

The safety and effectiveness of Янумет Лонг have not been established for the pediatric population (children and adolescents under 18 years of age). Its use in this age group is typically restricted based on the lack of established safety and effectiveness data.

---

Q: What does it mean that Янумет Лонг is a combination medicine?

The medicine is a fixed-dose combination product, meaning the tablet contains two distinct active ingredients. These are sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide), which work through different pathways to achieve better control of blood sugar.

---

Q: Is Янумет Лонг a type of insulin?

No, the medication is classified as an Antihyperglycaemic Combination product. While one of its ingredients, sitagliptin, helps to increase the body's natural release of insulin after meals, the tablet itself does not contain insulin.

---

Q: How is Янумет Лонг different from regular Янумет?

Янумет Лонг (Janumet XR) is an extended-release (XR) formulation, which is specifically designed for once-daily dosing. The regular Янумет (Janumet) is an immediate-release formulation that is typically taken twice a day.

---

Q: Why is this version called 'Long'?

The term 'Лонг' (meaning 'Long' or Extended-Release) refers to the specialized formulation designed to release the medication slowly and steadily into the body over an extended period. This prolonged-release mechanism supports once-daily dosing.

---

Q: What happens if I miss a dose of Янумет Лонг?

If a dose is missed, official instructions state that it should be taken when remembered, but two doses must never be taken together. Patients are instructed to follow the specific advice provided on how to handle a missed dose.

---

Q: Will Янумет Лонг cause weight loss?

Clinical trials and systematic reviews have studied the effect on body weight. Evidence from trials indicates that the combination medicine has been observed to be weight neutral or associated with a modest decrease in weight in some individuals.

---

Q: Is there a generic version of Янумет Лонг?

The brand name medication Янумет Лонг (Janumet XR) currently does not have a generic equivalent approved in the United States. Regulatory documents show that generic versions of the immediate-release components exist individually or in combination in other regions.

---

Q: Does Янумет Лонг affect my vitamin B12 levels?

Yes, metformin, one of the active components, has been known to lower Vitamin B12 levels. Regulatory advice suggests that B12 levels should be monitored at regular intervals, especially in patients with risk factors for deficiency.

---

Q: Are there different strengths or doses available for Янумет Лонг?

Yes, the medication is available in different fixed-dose strengths that vary in the amount of sitagliptin and metformin extended-release. These fixed-dose combinations allow for individualized therapy.

---

Q: Is there a link between Янумет Лонг and bone fractures?

Regulatory safety reviews of the drug's components have examined the potential for a link to bone fractures. Currently, no specific warning regarding increased fracture risk is mandated in the main safety sections of the official product information.

---

Q: Why do doctors prescribe Янумет Лонг instead of Metformin alone?

Official prescribing information indicates the combination is used when blood sugar control is inadequate with metformin monotherapy. The addition of sitagliptin works by targeting an additional metabolic pathway (incretin hormones) to achieve more significant overall improvement in blood sugar levels.

---

Q: Is it true that parts of the tablet pass into the stool?

Yes, the manufacturer's patient information describes this as a common occurrence with some extended-release medications, including the metformin component. The outer, non-digestible shell of the tablet may be noticed in the stool, but the active medication has still been absorbed by the body.

---

Q: Can Янумет Лонг be used to treat prediabetes?

No, the official indication for the drug is exclusively as an adjunct to diet and exercise for the treatment of Type 2 Diabetes Mellitus. Its use for treating prediabetes is not stated in the official regulatory documents.

How to Store and Dispose of Янумет Лонг

Янумет Лонг (Janumet XR) requires strict adherence to official storage conditions to maintain the stability of its extended-release formulation.

Storage Requirements

Store the tablets at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from both moisture and light and kept from freezing. Tablets must remain in a closed container and stored out of the reach of children.

Disposal Instructions

Official guidelines state that unused or expired tablets must be discarded through approved disposal channels, such as a medicine take-back program. It is prohibited to flush the medicine down a toilet or throw it into household trash to prevent environmental release. Do not keep medicine that is outdated or no longer needed.